Abstract: The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.

Abstract: The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.

Abstract: The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.

Abstract: The invention relates to a recombinant bacterium with E. coli hemolysin secretion system and increased expression and/or increased secretion of full length or partial HlyA.

Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.

Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.

Abstract: The invention relates to a transgenic non-human mammal whose cells express a constitutively active oncogenic mutant of the kinase-domain of the Raf-1 gene or a protein coded by a corresponding normal allele or derivative of the A, B, or c-Raf-1 gene.

Abstract: The invention relates to the use of a cell, which is charged with a micro-organism that contains foreign DNA, in particular a bacterial micro-organism, to produce a pharmaceutical composition. Preferably, the foreign DNA codes for a defined active agent and the pharmaceutical composition is designed for use in the prophylaxis or treatment of a disease that can be treated with said active agent.

Abstract: The invention relates to a transgenic non-human mammal whose cells express a constitutively active oncogenic mutant of the kinase-domain of the Raf-1 gene or a protein coded by a corresponding normal allele or derivative of the A, B, or c-Raf-1 gene.

Abstract: The invention relates to an isolated nucleic acid coding for at least a partial sequence of a protein kinase of the mitogenic signaling cascade, in particular c-raf, wherein the partial sequence interacts with VDAC or BAX channels in mitochondrial membranes, or with a nucleic acid hybridizing said nucleic acid or homologues or derivatives of said nucleic acid, to proteins or peptides coded for by such a nucleic acid and to a screening method.

Abstract: The invention relates to a microorganism with a nucleotide sequence coding for a cell antigen in which the following components are inserted and are expressible: I) a nucleotide sequence coding for at least one epitope of an antigen of a tumor cell and/or a nucleotide sequence for at least one epitope of an antigen that is specific for a tissue cell from which the tumor originates; II) an optional nucleotide sequence coding for a protein that stimulates cells of the immune system; IIIA) a nucleotide sequence for a transport system which makes it possible to express the expression product of components I) and, optionally, II) on the outer surface of the bacterium and/or secrete the expression product of component I) and, optionally, of component II); and/or IIIB) a nucleotide sequence for a protein used for lysing the microorganisms in the cytosol of mammalian cells and for intracellularly releasing plasmids which are contained in the lysed microorganisms; and IV) an activation sequence for expressing one or s

Abstract: The invention relates to a method for producing cells having an increased development potential from cells, which are removed from an organism, wherein the removed cells are cultivated in vitro, and wherein a native nuclear non-activated MAPKAP kinase of the cultivated cell is activated or wherein an activated MAPKAP kinase is transported into the cell nucleus of the cells.

Abstract: The invention relates to an enveloped microorganism in whose genome the following components are inserted and can be expressed: I) a nucleotide sequence that encodes a directly or indirectly, antiproliferatively or cytotoxically active expression product or a plurality of said expression products, II) a nucleotide sequence that encodes or is constitutively active for a blood plasma protein under the control of a activation sequence that can be activated in the microorganism, III) optionally, a nucleotide sequence that encodes or is constitutively active for a cell-specific ligand under the control of an activation sequence that can be activated in the microorganism, IV) a nucleotide sequence for a transport system that induces expression of the expression products of components I) and II) and optionally III) on the outer surface of the microorganism or that induces secretion of the expression products of component I) and expression of component II) and optionally component III) and that is preferably constitu

Abstract: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.